VT 1161

Drug Profile

VT 1161

Alternative Names: VT-1161

Latest Information Update: 27 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Viamet Pharmaceuticals
  • Developer Mycovia Pharmaceuticals; Viamet Pharmaceuticals
  • Class Antifungals; Azoles; Small molecules
  • Mechanism of Action 14-alpha demethylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Onychomycosis; Vulvovaginal candidiasis
  • No development reported Tinea pedis

Most Recent Events

  • 30 Jun 2018 Mycovia Pharmaceuticals plans a phase III trial for Vulvovaginal candidiasis (Recurrent, In adolescents, In adults) (PO, Capsules) (NCT03562156)
  • 26 Jun 2018 Mycovia Pharmaceuticals plans a phase III trial for vulvovaginal candidiasis (in children, adolescents and adults) (NCT03561701)
  • 04 Jun 2017 Adverse events data from a phase I trial in healthy volunteers released by Viamet Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top